U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Safety
  3. Recalls, Market Withdrawals, & Safety Alerts
  4. Sandoz, Inc. Issues Nationwide Recall of 13 Lots of Orphenadrine Citrate 100 mg Extended Release Tablets Due to Presence of a Nitrosamine Impurity
  1. Recalls, Market Withdrawals, & Safety Alerts

COMPANY ANNOUNCEMENT

Sandoz, Inc. Issues Nationwide Recall of 13 Lots of Orphenadrine Citrate 100 mg Extended Release Tablets Due to Presence of a Nitrosamine Impurity

When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company.

Read Announcement

Summary

Company Announcement Date:
FDA Publish Date:
Product Type:
Drugs
Reason for Announcement:
Recall Reason Description
Presence of a Nitrosamine Impurity
Company Name:
Sandoz, Inc.
Brand Name:
Brand Name(s)
Sandoz
Product Description:
Product Description
Orphenadrine Citrate 100 mg Extended Release (ER) Tablets

Company Announcement

Princeton, NJ, Sandoz Inc. (“Sandoz”) is initiating a voluntary recall of 13 lots (listed below) of oral Orphenadrine Citrate 100 mg Extended Release (ER) Tablets to the consumer level. The presence of a nitrosamine (N-methyl-N-nitroso-2-[(2-methylphenyl)phenylmethoxy]ethanamine (NMOA or Nitroso-Orphenadrine)) impurity, which has the potential to be above the U.S. Food and Drug Administration (FDA)’s Acceptable Daily Intake (ADI) limit of 26.5 ng/day, was detected in the lots during recent testing. These 13 lots of Orphenadrine Citrate ER Tablets were shipped to customers from August 2019 to April 2021.

Nitrosamines are substances with carcinogenic potency (substances that could cause cancer) when present above the allowable exposure limits. While the use of product belonging to the recalled lots may represent a risk to patients, to date, Sandoz has not received any reports of adverse events related to the presence of a nitrosamine impurity in the lot.

Orphenadrine Citrate ER Tablets are used as an adjunct to rest, physical therapy and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. The product is packaged in 100-count and 1000-count bottles and was distributed nationwide in the USA to wholesalers and distributors.

Product Name NDC Number Lot Number Expiration Date Date of Manufacture
Orphenadrine Citrate ER Tablets 0185-0022-01 JX6411 05/2022 5/24/2019
Orphenadrine Citrate ER Tablets 0185-0022-01 JX6413 05/2022 5/24/2019
Orphenadrine Citrate ER Tablets 0185-0022-01 KC0723 08/2022 8/21/2019
Orphenadrine Citrate ER Tablets 0185-0022-01 KC3303 08/2022 8/21/2019
Orphenadrine Citrate ER Tablets 0185-0022-01 KE4348 11/2022 11/6/2019
Orphenadrine Citrate ER Tablets 0185-0022-01 KE7169 11/2022 11/6/2019
Orphenadrine Citrate ER Tablets 0185-0022-01 KE4349 11/2022 11/6/2019
Orphenadrine Citrate ER Tablets 0185-0022-01 KL3199 03/2023 3/3/2020
Orphenadrine Citrate ER Tablets 0185-0022-01 KM0072 03/2023 3/3/2020
Orphenadrine Citrate ER Tablets 0185-0022-10 KS3939+ 03/2023 3/3/2020
Orphenadrine Citrate ER Tablets 0185-0022-01 LA7704 10/2023 10/6/2020
Orphenadrine Citrate ER Tablets 0185-0022-01 LA7703 10/2023 10/6/2020
Orphenadrine Citrate ER Tablets 0185-0022-01 LA9243 11/2023 11/18/2020

+ 1,000-count bottle

This recall of Orphenadrine Citrate ER Tablets is specific to the lots listed above and does not apply to any other strengths of Sandoz Orphenadrine Citrate ER Tablets nor to other lot numbers of the product. Any product returned that is not associated with this recall will be destroyed, and no credit will be issued.

Sandoz is notifying its wholesalers and distributors by mail and is arranging for the return of all recalled product. Wholesalers and distributors that have Orphenadrine Citrate ER Tablets subject to this recall should immediately stop distribution of the recalled product and quarantine and return all recalled product in their inventory.

Consumers who have Orphenadrine Citrate ER Tablets being recalled should stop taking the recalled product and immediately consult with their physician to obtain another prescription. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Retailers and consumers should contact Sedgwick directly by phone at 844-491-7869 or email at sandoz4887@sedgwick.com to return the recalled product. Representatives are available Monday – Friday, 8:00 am – 5:00 pm ET.

To report an adverse reaction, please contact Sandoz by phone at (800) 525-8747 or by email at qa.drugsafety@sandoz.com. Customer service agents are available Monday – Friday from 8:30 am to 5:00 pm ET.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the report Online
  • Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Company Contact Information

Consumers:
Sedgwick
844-491-7869
sandoz4887@sedgwick.com
Media:
Leslie Pott
201-354-0279
 
Back to Top